-
M.
Kempkes-Koch,
M.
Fobker,
Michael
Erren,
C.
August,
U.
Gerhardt,
B.
Suwelack,
H.
Hohage
(2001)
Cyclosporine A metabolite AM19 as a potential biomarker in urine for CSA nephropathy.
Transplantation proceedings, 33 3
-
A.
Bader,
T.
Hansen,
G.
Kirchner,
C.
Allmeling,
A.
Haverich,
J.
Borlak
(2000)
Primary porcine enterocyte and hepatocyte cultures to study drug oxidation reactions
British Journal of Pharmacology, 129
-
T.
Aoyama,
S.
Yamano,
D.
Waxman,
D.
Lapenson,
U.
Meyer,
V.
Fischer,
R.
Tyndale,
T.
Inaba,
W.
Kalow,
H.
Gelboin
(1989)
Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.
The Journal of biological chemistry, 264 18
-
A.
Möller,
K.
Iwasaki,
A.
Kawamura,
Y.
Teramura,
T.
Shiraga,
T.
Hata,
A.
Schäfer,
N.
Undre
(1999)
The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects.
Drug metabolism and disposition: the biological fate of chemicals, 27 6
-
M.
Sattler,
F.
Guengerich,
C.
Yun,
U.
Christians,
Sewing
Kf
(1992)
Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.
Drug metabolism and disposition: the biological fate of chemicals, 20 5
-
D.
Hesselink,
R.
Schaik,
I.
Heiden,
M.
Werf,
P.
Gregoor,
J.
Lindemans,
W.
Weimar,
T.
Gelder
(2003)
Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR‐1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus
Clinical Pharmacology & Therapeutics, 74
-
P.
Kuehl,
Jiong
Zhang,
Yvonne
Lin,
J.
Lamba,
M.
Assem,
J.
Schuetz,
P.
Watkins,
A.
Daly,
S.
Wrighton,
S.
Hall,
P.
Maurel,
M.
Relling,
Cynthia
Brimer,
K.
Yasuda,
R.
Venkataramanan,
S.
Strom,
K.
Thummel,
M.
Boguski,
E.
Schuetz
(2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
Nature Genetics, 27
-
R.
Obach,
A.
Reed-Hagen
(2002)
Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach.
Drug metabolism and disposition: the biological fate of chemicals, 30 7
-
Kenneth
Korzekwa,
N.
Krishnamachary,
M.
Shou,
A.
Ogai,
R.
Parise,
A.
Rettie,
Frank
Gonzalez,
Timothy
Tracy
(1998)
Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites.
Biochemistry, 37 12
-
J.
Bleck,
H.
Schlitt,
U.
Christians,
R.
Schottmann,
C.
Thiesemann,
S.
Strohmeyer,
K.
Kohlhaw,
K.
Wonigeit,
R.
Pichlmayr,
K.
Sewing
(2004)
Ciclosporin metabolite pattern in blood and urine of kidney graft patients in relation to liver function
European Journal of Clinical Pharmacology, 40
-
(1999)
FK 506 nephrotoxicity
-
Kazuko
Nagase,
K.
Iwasaki,
Katsuko
Nozaki,
K.
Noda
(1994)
Distribution and Protein Binding of FK506, a Potent Immunosuppressive Macrolide Lactone, in Human Blood and Its Uptake by Erythrocytes
Journal of Pharmacy and Pharmacology, 46
-
R.
Givens,
Yvonne
Lin,
A.
Dowling,
K.
Thummel,
J.
Lamba,
E.
Schuetz,
P.
Stewart,
P.
Watkins
(2003)
CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.
Journal of applied physiology, 95 3
-
W.
Jusko,
A.
Thomson,
J.
Fung,
P.
Mcmaster,
Steven
Wong,
E.
Zylber‐katz,
U.
Christians,
M.
Winkler,
W.
Fitzsimmons,
R.
Lieberman,
James
McBride,
Masakazu
Kobayashi,
V.
Warty,
S.
Soldin
(1995)
Consensus Document: Therapeutic Monitoring of Tacrolimus (FK‐506)
Therapeutic Drug Monitoring, 17
-
U.
Christians,
K.
Kohlhaw,
J.
Budniak,
J.
Bleck,
R.
Schottmann,
H.
Schlitt,
V.
Almeida,
M.
Deters,
K.
Wonigeit,
R.
Pichlmayr,
K.
Sewing
(2004)
Ciclosporin metabolite pattern in blood and urine of liver graft recipients
European Journal of Clinical Pharmacology, 41
-
J.
Ader,
L.
Rostaing
(1998)
Cyclosporin nephrotoxicity: pathophysiology and comparison with FK‐506
Current Opinion in Nephrology and Hypertension, 7
-
R.
Kreutz,
H.
Zürcher,
S.
Kain,
P.
Martus,
G.
Offermann,
J.
Beige
(2004)
The effect of variable CYP3A5 expression on cyclosporine dosing, blood pressure and long-term graft survival in renal transplant patients.
Pharmacogenetics, 14 10
-
L.
Scott,
K.
McKeage,
S.
Keam,
G.
Plosker
(2003)
Tacrolimus: a further update of its use in the management of organ transplantation.
Drugs, 63 12
-
V.
Haufroid,
M.
Mourad,
Valérie
Kerckhove,
Jeremie
Wawrzyniak,
M.
Meyer,
D.
Eddour,
J.
Malaise,
D.
Lison,
J.
Squifflet,
P.
Wallemacq
(2004)
The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients.
Pharmacogenetics, 14 3
-
A.
Ojo,
P.
Held,
F.
Port,
R.
Wolfe,
A.
Leichtman,
E.
Young,
J.
Arndorfer,
L.
Christensen,
R.
Merion
(2003)
Chronic renal failure after transplantation of a nonrenal organ.
The New England journal of medicine, 349 10
-
Yoichi
Naritomi,
S.
Terashita,
Sumihisa
Kimura,
A.
Suzuki,
A.
Kagayama,
Yuichi
Sugiyama
(2001)
Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans.
Drug metabolism and disposition: the biological fate of chemicals, 29 10
-
(1999)
FK506 nephrotoxicity. Renal Fail 21:319–329
-
(1989)
doses and concentration-to-dose ratio in renal transplant recipients. Transplantation
-
S.
Hortelano,
M.
Castilla,
A.
Torres,
A.
Tejedor,
L.
Boscá
(2000)
Potentiation by nitric oxide of cyclosporin A and FK506-induced apoptosis in renal proximal tubule cells.
Journal of the American Society of Nephrology : JASN, 11 12
-
Toshipumi
Shiraga,
H.
Matsuda,
Kazuko
Nagase,
K.
Iwasaki,
K.
Noda,
H.
Yamazaki,
T.
Shimada,
Y.
Funae
(1994)
Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes.
Biochemical pharmacology, 47 4
-
L.
Kamdem,
F.
Streit,
U.
Zanger,
J.
Brockmöller,
M.
Oellerich,
V.
Armstrong,
L.
Wojnowski
(2005)
Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus.
Clinical chemistry, 51 8
-
G.
Lhoëst,
R.
Hertsens,
R.
Verbeeck,
N.
Maton,
P.
Wallemacq,
J.
Dehoux,
D.
Latinne
(2001)
In vitro immunosuppressive activity of tacrolimus dihydrodiol precursors obtained by chemical oxidation and identification of a new metabolite of SDZ-RAD by electrospray and electrospray-linked scan mass spectrometry.
Journal of mass spectrometry : JMS, 36 8
-
M.
Paine,
M.
Khalighi,
J.
Fisher,
D.
Shen,
K.
Kunze,
C.
Marsh,
J.
Perkins,
K.
Thummel
(1997)
Characterization of interintestinal and intraintestinal variations in human CYP3A-dependent metabolism.
The Journal of pharmacology and experimental therapeutics, 283 3
-
Hongxia
Zheng,
S.
Webber,
A.
Zeevi,
E.
Schuetz,
Jiong
Zhang,
P.
Bowman,
G.
Boyle,
Y.
Law,
S.
Miller,
J.
Lamba,
G.
Burckart
(2003)
Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms
American Journal of Transplantation, 3
-
Weili
Huang,
Yvonne
Lin,
D.
McConn,
J.
Calamia,
R.
Totah,
N.
Isoherranen,
Mary
Glodowski,
K.
Thummel
(2004)
EVIDENCE OF SIGNIFICANT CONTRIBUTION FROM CYP3A5 TO HEPATIC DRUG METABOLISM
Drug Metabolism and Disposition, 32
-
P.
Wallemacq,
G.
Lhoëst,
D.
Latinne,
M.
Bruyere
(1989)
Isolation, characterization and in vitro activity of human cyclosporin A metabolites.
Transplantation Proceedings, 21
-
C.
Brooks,
S.
Cramer,
T.
Rosano
(1993)
Preparative chromatographic purification of cyclosporine metabolites.
Clinical chemistry, 39 3
-
K.
Iwasaki,
Y.
Miyazaki,
Y.
Teramura,
A.
Kawamura,
Z.
Tozuka,
T.
Hata,
N.
Undre
(1996)
Binding of tacrolimus (FK506) with human plasma proteins re-evaluation and effect of mycophenolic acid.
Research communications in molecular pathology and pharmacology, 94 3
-
K.
Iwasaki,
T.
Shiraga,
K.
Nagase,
Z.
Tozuka,
K.
Noda,
S.
Sakuma,
T.
Fujitsu,
K.
Shimatani,
A.
Sato,
M.
Fujioka
(1993)
Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone.
Drug metabolism and disposition: the biological fate of chemicals, 21 6
-
(1998)
© 1999 Cancer Research Campaign Article no. bjoc.1998.0292
-
Yvonne
Lin,
A.
Dowling,
S.
Quigley,
F.
Farin,
Jiong
Zhang,
J.
Lamba,
E.
Schuetz,
K.
Thummel
(2002)
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.
Molecular pharmacology, 62 1
-
L.
Mancinelli,
L.
Frassetto,
L.
Floren,
D.
Dressler,
Steve
Carrier,
I.
Bekersky,
L.
Benet,
U.
Christians
(2001)
The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups
Clinical Pharmacology & Therapeutics, 69
-
W.
Jusko,
W.
Piekoszewski,
G.
Klintmalm,
M.
Shaefer,
M.
Hebert,
A.
Piergies,
Charles
Lee,
P.
Schechter,
Q.
Mekki
(1995)
Pharmacokinetics of tacrolimus in liver transplant patients
Clinical Pharmacology & Therapeutics, 57
-
Yang
Dai,
K.
Iwanaga,
Yvonne
Lin,
M.
Hebert,
C.
Davis,
Weili
Huang,
E.
Kharasch,
K.
Thummel
(2004)
In vitro metabolism of cyclosporine A by human kidney CYP3A5.
Biochemical pharmacology, 68 9
-
J.
Lamba,
Yvonne
Lin,
E.
Schuetz,
K.
Thummel
(2002)
Genetic contribution to variable human CYP3A-mediated metabolism.
Advanced drug delivery reviews, 54 10
-
A.
Lampen,
U.
Christians,
F.
Guengerich,
P.
Watkins,
J.
Kolars,
A.
Bader,
A.
Gonschior,
H.
Dralle,
I.
Hackbarth,
K.
Sewing
(1995)
Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability.
Drug metabolism and disposition: the biological fate of chemicals, 23 12
-
E.
Thervet,
D.
Anglicheau,
B.
King,
M.
Schlageter,
B.
Cassinat,
P.
Beaune,
C.
Legendre,
A.
Daly
(2003)
Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12
Transplantation, 76
-
K.
Iwasaki,
T.
Shiraga,
H.
Matsuda,
K.
Nagase,
Y.
Tokuma,
T.
Hata,
Y.
Fujii,
S.
Sakuma,
T.
Fujitsu,
A.
Fujikawa
(1995)
Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506.
Drug metabolism and disposition: the biological fate of chemicals, 23 1